Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours Β· Estimated delivery Aug 18 - Aug 23
Tear open the stick sachet 3
Prioritizing sleep quality and duration enhances the regenerative environment in which peptides operate
doi: 10.1007/s11916-020-00898-0
IF item } ( item } Reactivity item } Q (FAQpage } No files available
Quick Comparison: Eloralintide vs Retatrutide Attribute Eloralintide Retatrutide Developer Eli Lilly Eli Lilly Class Selective amylin receptor agonist (LY-3841136 class) Triple agonist (LY3437943) Receptors targeted Amylin receptor only GIP + GLP-1 + glucagon Administration in trials Once weekly Once weekly, subcutaneous Phase 2 population 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes Phase 2 duration 48 weeks 48 weeks Reported mean weight reduction 9.5%-20.1% across arms vs 0.4% placebo (~20.1% at 9 mg) Up to 24.2% (~26.2 kg / ~58 lb) at the highest dose Tolerability signal Mild-to-moderate GI events
* Correspondence: Omid Akbari, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
